<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05040971</url>
  </required_header>
  <id_info>
    <org_study_id>NN9536-4734</org_study_id>
    <secondary_id>U1111-1253-1956</secondary_id>
    <secondary_id>2020-002939-29</secondary_id>
    <nct_id>NCT05040971</nct_id>
  </id_info>
  <brief_title>Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes</brief_title>
  <acronym>STEP 10</acronym>
  <official_title>Efficacy and Safety of Subcutaneous Semaglutide 2.4 mg Once-weekly in Subjects With Obesity and Prediabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study looks at how well a new medicine, called semaglutide, works at helping people with&#xD;
      obesity and prediabetes.&#xD;
&#xD;
      This study will look at how much weight participants lose, and if participants can go from&#xD;
      having blood sugar that is higher than normal (prediabetes) to having normal blood sugar.&#xD;
&#xD;
      Semaglutide is compared to a &quot;dummy&quot; medicine. The &quot;dummy&quot; medicine looks like semaglutide&#xD;
      but has no effect on the body.&#xD;
&#xD;
      In addition to taking the medicine, participants will have talks with study staff about&#xD;
      healthy food choices, how to be more physically active and what participants can do to lose&#xD;
      weight.&#xD;
&#xD;
      Participants will either get semaglutide or &quot;dummy&quot; medicine - which treatment they get is&#xD;
      decided by chance. Participants are 2 times as likely to get semaglutide as &quot;dummy&quot; medicine.&#xD;
&#xD;
      Participants will need to take 1 injection once a week. The study medicine is injected with a&#xD;
      thin needle in a skin fold in the stomach, thigh or upper arm.&#xD;
&#xD;
      The study will last for about 19 months. Participants have to take the study medicine every&#xD;
      week for the first 12 months. The last 7 months participants will not take any medication.&#xD;
&#xD;
      Participants will have 14 clinic visits and 1 phone call with the study staff. At 9 of the&#xD;
      clinic visits Participants will have blood samples taken. Women cannot take part if pregnant,&#xD;
      breast-feeding or plan to become pregnant during the study period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2021</start_date>
  <completion_date type="Anticipated">July 24, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 9, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>From randomisation (week 0) to end of treatment (week 52)</time_frame>
    <description>Percentage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change to normoglycemia (Normoglycemia is defined as having both HbA1c below 6.0% (below 42 mmol/mol) and FPG below 5.5 mmol/L (below 99 mg/dL)</measure>
    <time_frame>From randomisation (week 0) to end of treatment (week 52)</time_frame>
    <description>Count of subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c (glycated haemoglobin)</measure>
    <time_frame>From randomisation (week 0) to end of treatment (week 52)</time_frame>
    <description>Percentage-points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FPG (fasting plasma glucose)</measure>
    <time_frame>From randomisation (week 0) to end of treatment (week 52)</time_frame>
    <description>measured in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference</measure>
    <time_frame>From randomisation (week 0) to end of treatment (week 52)</time_frame>
    <description>measured in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic blood pressure</measure>
    <time_frame>From randomisation (week 0) to end of treatment (week 52)</time_frame>
    <description>measured in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipids - Triglycerides</measure>
    <time_frame>From randomisation (week 0) to end of treatment (week 52)</time_frame>
    <description>percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipids - Total cholesterol</measure>
    <time_frame>From randomisation (week 0) to end of treatment (week 52)</time_frame>
    <description>percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipids - High density lipoprotein (HDL) cholesterol</measure>
    <time_frame>From randomisation (week 0) to end of treatment (week 52)</time_frame>
    <description>percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipids - low density lipoprotein (LDL) cholesterol</measure>
    <time_frame>From randomisation (week 0) to end of treatment (week 52)</time_frame>
    <description>percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipids - Very low density lipoprotein (VLDL) cholesterol</measure>
    <time_frame>From randomisation (week 0) to end of treatment (week 52)</time_frame>
    <description>percentage</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">201</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Semaglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive subcutaneus (s.c.) semaglutide 2.4 mg once weekly for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (semaglutide)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive subcutaneus (s.c.) placebo (semaglutide) once weekly for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide 2.4 mg</intervention_name>
    <description>Administered subcutaneously (s.c., under the skin) once weekly as well as reduced-calorie diet and increased physical activity for 52 weeks. Doses gradually increased to 2.4 mg</description>
    <arm_group_label>Semaglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered subcutaneously once weekly (s.c., under the skin) as well as reduced-calorie diet and increased physical activity for 52 week</description>
    <arm_group_label>Placebo (semaglutide)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged greater than or equal to 18 years at the time of signing informed&#xD;
             consent.&#xD;
&#xD;
          -  BMI greater than or equal to 30.0 kg/m^2&#xD;
&#xD;
          -  Prediabetes defined as at least one of the following:&#xD;
&#xD;
               -  HbA1c between 6.0 and 6.4 percent (42 and 47 mmol/mol) (both inclusive) as&#xD;
                  measured by central laboratory at screening.&#xD;
&#xD;
               -  FPG between 5.5 and 6.9 mmol/L (99 and 125 mg/dL) (both inclusive) as measured by&#xD;
                  central laboratory at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of type 1 or type 2 diabetes.&#xD;
&#xD;
          -  Treatment with glucose-lowering agent(s) within 90 days before screening.&#xD;
&#xD;
          -  HbA1c greater than or equal to 6.5 percent (greater than or equal to 48 mmol/mol) as&#xD;
             measured by central laboratory at screening.&#xD;
&#xD;
          -  FPG greater than or equal to 7.0mmol/L (126 mg/dL) as measured by central laboratory&#xD;
             at screening.&#xD;
&#xD;
        A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before&#xD;
        screening irrespective of medical records.&#xD;
&#xD;
          -  Treatment with any medication for the indication of obesity within the past 90 days&#xD;
             before screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Transparency (dept. 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <phone>(+1) 866-867-7178</phone>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2T 5C7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2V 4J2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3Z 2N6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1G 1A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6S 0C6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Concord</city>
        <state>Ontario</state>
        <zip>L4K 4M2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8M 1K7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5W 6A2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4P 1P2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6G 1M2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4N 2W2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4T 1Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Terrebonne</city>
        <state>Quebec</state>
        <zip>J6X 4P7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jyväskylä</city>
        <zip>40620</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>University Of Helsinki</city>
        <zip>00014</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>&quot;According to the Novo Nordisk disclosure commitment on novonordisk-trials.com&quot;</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

